Brokerages forecast that Definitive Healthcare Corp. (NASDAQ:DH – Get Rating) will report $0.05 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Definitive Healthcare’s earnings. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Definitive Healthcare will report full year earnings of $0.24 per share for the current fiscal year, with EPS estimates ranging from $0.22 to $0.26. For the next year, analysts expect that the business will report earnings of $0.40 per share, with EPS estimates ranging from $0.36 to $0.45. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Definitive Healthcare.
Definitive Healthcare (NASDAQ:DH – Get Rating) last posted its earnings results on Wednesday, February 23rd. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $46.31 million for the quarter, compared to analysts’ expectations of $44.78 million.
Several brokerages have commented on DH. Credit Suisse Group decreased their price objective on shares of Definitive Healthcare from $30.00 to $24.00 and set a “neutral” rating for the company in a research note on Thursday, February 24th. Barclays decreased their price objective on shares of Definitive Healthcare from $26.00 to $23.00 in a research note on Thursday, February 24th. Canaccord Genuity Group raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating and cut their target price for the company from $46.00 to $28.00 in a report on Thursday, February 24th. Canaccord Genuity Group raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Thursday, February 24th. Finally, Zacks Investment Research lowered shares of Definitive Healthcare from a “hold” rating to a “sell” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $37.00.
DH stock traded up $0.02 during trading on Friday, reaching $16.47. The company had a trading volume of 1,123,498 shares, compared to its average volume of 621,150. The firm has a 50-day simple moving average of $22.72 and a 200-day simple moving average of $25.49. The company has a quick ratio of 3.21, a current ratio of 3.21 and a debt-to-equity ratio of 0.18. Definitive Healthcare has a twelve month low of $14.76 and a twelve month high of $50.30.
In related news, CFO Richard Douglas Booth bought 2,374 shares of the firm’s stock in a transaction on Thursday, March 3rd. The shares were bought at an average price of $21.06 per share, with a total value of $49,996.44. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Charles Haywood sold 18,315 shares of the business’s stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $15.46, for a total transaction of $283,149.90. The disclosure for this sale can be found here. Corporate insiders own 17.52% of the company’s stock.
A number of large investors have recently modified their holdings of the business. Advisor Group Holdings Inc. purchased a new stake in shares of Definitive Healthcare during the third quarter worth approximately $26,000. Legal & General Group Plc purchased a new stake in shares of Definitive Healthcare during the fourth quarter worth approximately $29,000. Fifth Third Bancorp increased its stake in shares of Definitive Healthcare by 78.5% during the first quarter. Fifth Third Bancorp now owns 1,185 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the period. Hardy Reed LLC purchased a new stake in shares of Definitive Healthcare during the first quarter worth approximately $76,000. Finally, Steph & Co. purchased a new position in Definitive Healthcare in the fourth quarter valued at approximately $88,000. Institutional investors own 99.42% of the company’s stock.
Definitive Healthcare Company Profile (Get Rating)
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Definitive Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Definitive Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.